AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Press Archive
- Charles Francis: Weakening eye surgery laws places WV patients in jeopardy
- Mark D. Mayle, MD - 2022 Secretariat Award Recipients
- Dr. Larry Schwab recognized with 2020 International Blindness Prevention Award
- Wow Moment with Joseph A. LoCasio | Bio-Tissue | #WowWednesdays
- WVU Today | Moore, Oppe named recipients of Heebink award for Distinguished Service
- Cornea Transplant Restores Young Boy’s Sight After Fishing Accident
- Keep your eyes healthy and safe in the workplace
- Glaucoma Awareness Month
- Ophthalmologists Say 90 Percent of Work-Related Eye Injuries Can be Avoided by Wearing Eye Protection
- Five Tips to Avoid Toy-Related Eye Injuries
- Details
This retrospective review shows that the introduction of corneal collagen crosslinking may have reduced the number of keratoplasty procedures for keratoconus.
- Details
The FDA has issued a final guidance document for industry and FDA staff on minimally invasive glaucoma surgical (MIGS) devices.
- Details
Ocular Therapeutix announced promising topline results from a phase 2 clinical trial of sustained-released dexamethasone for inflammatory dry eye disease.
Read more: Sustained-released dexamethasone shows promise in dry eye
- Details
Retrospective review shows anti-VEGF treatment should be performed cautiously in patients with retinal angiomatous proliferation (RAP).
Read more: Risk factors for RPE tears after ranibizumab for RAP
- Details
Embattled drugmaker Valeant Pharmaceuticals has struck a deal with Walgreens to distribute some of its drugs at a 10% discount.
- Details
Mundipharma and Purdue Pharma Canada have acquired marketing rights to Merck’s glaucoma portfolio outside of the United States.
Read more: Merck continues to divest its ophthalmology products